Cardiometabolic Disease Market

• The growing prevalence of cardiometabolic disorders boosts the market growth

One among the primary causes of death worldwide is due to cardiometabolic disorders (CMDs). An unhealthy lifestyle, physical inactivity, smoking, and improper food are the key contributors to these diseases. CMDs include chronic renal failure, diabetes mellitus, and cardiovascular illnesses (CVDs). For instance, the WHO reports that the main cause of mortality worldwide is cardiovascular diseases (CVDs), which claim an estimated 17.9 million lives annually. Coronary heart disease, rheumatic heart disease, cerebrovascular disease, and other illnesses are heart and blood vessel disorders known as CVDs.

Heart attacks and strokes are responsible for more than four out of every five CVD deaths, and one-third of these deaths happen before age 70. Unhealthy eating habits, usage of tobacco products, and abusing alcohol are the main behavioral risk factors for heart disease and stroke. Individuals may experience elevated blood pressure, elevated blood glucose, elevated blood lipids, as well as overweight and obesity as a result of behavioral risk factors. The growing prevalence of CVDs is anticipated to boost the market CAGR during the coming years.

Health-related technology has developed quickly due to developments in computers, electronics, telecommunication, and medicine. For instance, the genetic preventative strategy can pinpoint those most at risk for the disease, enabling early intervention to improve their lifestyles. The NHS began using genomic analysis to determine the likelihood of developing heart disease in March 2021. The UK biotech company NHS, Genomics plc, and an Oxford University spin-off are collaborating on a pilot trial that will utilize genetic data to forecast the risk of heart disease.

Genomics plc's integrated risk instrument (IRT) will calculate each patient's chance of having CVD during the next ten years. According to the business, applying the IRT to everyone in the UK between the ages of 40 and 60 would allow for identifying more than 650,000 people with high CVD risk who are currently ignored by screening. In addition, the traditional healthcare system has been greatly enhanced by current advancements in the Internet of Things (IoT), cloud computing, and artificial intelligence (AI). Thus, such factors are driving the Cardiometabolic Disease market revenue.

The aging population is a significant factor influencing the Global Cardiometabolic Disease Market Industry. As individuals age, the risk of developing cardiometabolic conditions escalates, leading to a higher demand for healthcare services and interventions. By 2035, it is anticipated that a substantial portion of the global population will be over the age of 65, further exacerbating the prevalence of these diseases. This demographic shift necessitates tailored healthcare solutions, thereby driving market growth and innovation in treatment strategies.

The Global Cardiometabolic Disease Market Industry is poised for substantial growth, with projections indicating a market value of 192.7 USD Billion in 2024 and an anticipated increase to 2056.9 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate (CAGR) of 24.02% from 2025 to 2035. Such figures underscore the increasing focus on addressing cardiometabolic diseases through innovative therapies, preventive measures, and enhanced healthcare access.

Growing awareness regarding cardiometabolic diseases is influencing the Global Cardiometabolic Disease Market Industry positively. Public health campaigns and educational initiatives are informing populations about the risks associated with these conditions, leading to proactive health management. For example, initiatives by health organizations have resulted in a notable increase in screening rates for diabetes and hypertension. This heightened awareness is likely to drive demand for diagnostic tools and treatment options, contributing to a projected CAGR of 24.02% from 2025 to 2035.

Technological innovations play a pivotal role in shaping the Global Cardiometabolic Disease Market Industry. The emergence of digital health solutions, including telemedicine and wearable devices, facilitates real-time monitoring and management of cardiometabolic conditions. For instance, remote patient monitoring systems have shown to improve patient adherence to treatment regimens, thereby enhancing outcomes. As these technologies become more integrated into healthcare practices, they are expected to contribute significantly to the market's expansion, potentially reaching a valuation of 2056.9 USD Billion by 2035.

Government policies and funding aimed at combating cardiometabolic diseases are crucial drivers of the Global Cardiometabolic Disease Market Industry. Many countries are implementing national strategies to reduce the burden of these diseases through enhanced healthcare access and preventive measures. For instance, increased funding for research and development of new therapies is expected to foster innovation in treatment options. Such initiatives not only improve patient outcomes but also stimulate market growth, as evidenced by the rising investments in healthcare infrastructure.

The Global Cardiometabolic Disease Market Industry is experiencing a surge in demand due to the increasing prevalence of conditions such as diabetes, hypertension, and obesity. According to recent data, approximately 1 in 3 adults globally are affected by these diseases, leading to a heightened focus on prevention and management strategies. This trend is expected to drive the market value to an estimated 192.7 USD Billion in 2024. As healthcare systems adapt to this growing burden, investments in innovative therapies and lifestyle interventions are likely to expand, further propelling the market's growth.

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Cardiometabolic Disease market area will dominate this market. Rising healthcare product demand and expanding economies are to blame for this region's rise. Another significant driver of the market expansion is the growing awareness of cardiometabolic disease among European consumers and the expansion of the healthcare sector.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: CARDIOMETABOLIC DISEASE MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe's Cardiometabolic Disease market accounted for the second-largest market share in 2022. Rising R&D spending, high healthcare costs, and a well-established healthcare sector in this area. Further, the German market of Cardiometabolic Disease held the largest market share, and the UK market of Cardiometabolic Disease was the fastest growing market in the European region

The Asia-Pacific Cardiometabolic Disease Market is expected to grow at the fastest CAGR from 2023 to 2032. Due to the region's rapidly expanding medical infrastructures, stringent government regulations on public healthcare, and prominent manufacturers' adoption of various market expansion tactics, Asia Pacific had a sizeable market share during the anticipated period. Moreover, China’s market of Cardiometabolic Disease held the largest market share, and the Indian market of Cardiometabolic Disease was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in R&D to expand their product lines, which will help the market of Cardiometabolic Disease. Companies are also undertaking strategic activities to expand their global footprint, with important market developments including contractual agreements, mergers and acquisitions, new product launches, and collaboration with other companies.

In recent years, the Cardiometabolic Disease industry has offered some of the most significant products. Major players in the market of Cardiometabolic Disease include Cardax, Inc., Novartis AG, Novo Nordisk A/S, Eli Lilly and Company, Bayer AG, Allergan, Boehringer Ingelheim, International GmbH, AstraZeneca, and other players.

Cardax is a biopharmaceutical business in the development stage focused on creating medications for chronic conditions characterized by inflammation. An astaxanthin dietary supplement for inflammatory health, ZanthoSyn is marketed by Cardax, a consumer health firm. Until now, Cardax concentrated on creating medications for illnesses brought on by inflammation. CDX-101, the company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the pre-clinical pharmaceutical candidate for macular degeneration, may be made commercially available by Cardax.

The healthcare corporation Novartis AG specializes in developing, producing, and marketing prescription and over-the-counter drugs, as well as products for eye care. In addition, it offers medicines for treating solid tumors, immunological disorders, infections, cardiovascular illness, ophthalmic and respiratory diseases, dermatological issues, neurological disorders, cancer, and neurological disorders. Through Sandoz, the business provides biosimilars and generic medications. Through the Novartis Institutes for BioMedical Research (NIBR), Novartis researches several disease-related fields. The corporation has a network of subsidiaries and offices in the Americas, the Middle East, Europe, Africa, and Asia-Pacific. Basel, Switzerland, serves as the headquarters of Novartis.